NEOSENT: Neoadjuvant anti-PD-1 therapy for patients with high-risk clinical stage II melanoma with a scheduled sentinel lymph node biopsy.

Authors: Milton Jose De Barros E. Silva, Matheus Lobo, Andre Molina, Ivan Santos Filho, Manoel Coelho, Monique Celeste Tavares, Joao Paulo S. N. Lima, Rafaela Brito De Paula, Clovis Pinto, João Pedreira Duprat Neto

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9609

Source: Full article

---

Abstract

TPS9609